Abstract | AIM: METHODS: The clinical data of 80 patients treated with topotecan- (n = 45) or belotecan- (n = 35) based chemotherapy as at least a second-line chemotherapy were reviewed retrospectively between July 2001 and December 2007. Response was evaluated using the Response Evaluation Criteria in Solid Tumours (RECIST) and serum CA-125 levels. Hematological toxicity was examined according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0. Time to progressive disease (TTPD), chemotherapy-specific survival (CSS) and overall survival (OS) according to the 2 chemotherapies were evaluated by the Kaplan-Meier analysis with the log-rank test. RESULTS: CONCLUSIONS:
|
Authors | Hee Seung Kim, Noh Hyun Park, Sokbom Kang, Sang-Soo Seo, Hyun Hoon Chung, Jae Weon Kim, Yong Sang Song, Soon-Beom Kang |
Journal | The journal of obstetrics and gynaecology research
(J Obstet Gynaecol Res)
Vol. 36
Issue 1
Pg. 86-93
(Feb 2010)
ISSN: 1447-0756 [Electronic] Australia |
PMID | 20178532
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- belotecan
- Topotecan
- Cisplatin
- Camptothecin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Carcinoma
(drug therapy)
- Cisplatin
(administration & dosage)
- Epithelium
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Ovarian Neoplasms
(drug therapy)
- Retrospective Studies
- Survival Analysis
- Topotecan
(administration & dosage, adverse effects, therapeutic use)
|